Pharmaceuticals and Medicines
Please find all related articles below.
In a recent public consultation, the European Medicines Agency (EMA) solicited stakeholders’ views about its draft proposal for a transparency addendum pertaining to the content of the EU portal and database that will be set up for the implementation of the Clinical Trial Regulation No 536/2014. The express aim of the latter is to provide more information on clinical trials and their result in Europe.
The consultation on the ’Draft proposal for an addendum, on transparency, to (...)
Brussels, 18 November – Today marks the 7th European Antibiotic Awareness Day (EAAD) (1) which promotes a more prudent use of antibiotics to tackle the growing challenge of multi-drug resistant ‘superbugs’ (2). Around 25,000 patients die every year in the European Union (EU) as a result of infections caused by antibiotic-resistant bacteria. Preventing the spread of antibiotic resistance will lead to significant health service savings since related costs amount to (...)
A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anesthetics.
Brussels, 17 November 2014 - The report by the European Association of Hospital Pharmacists (EAHP), surveyed the experiences of over 600 hospital pharmacists in 36 European (...)
Brussels, 30 October 2014 - On 29 July 2014, the European Ombudsman opened an own-initiative inquiry towards the European Commission concerning transparency and public participation in relation to the TTIP negotiations (OI/10/2014/RA). The present public consultation concerns that inquiry.
The outcome of the TTIP negotiations could have a significant impact on the lives of citizens. The aim of the Ombudsman’s inquiry is to help ensure that the public can follow the progress of these (...)
October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1).
Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
Health is a fundamental universal right and access to medicines is part of it. The EU and its Member States are committed to universal and equitable access to healthcare. Nevertheless, millions of European patients suffer from the lack of affordability of many life-saving medicines across Europe.
Download the event’s invitation
* See the event’s poster
An event under the auspices of MEPs Nessa CHILDERS (S&D, IE), Beatriz BECERRA BASTERRECHEA (ALDE, ES), Kostas (...)
October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4).
“I would like to applaud President-elect (...)
October 8 2014, Brussels - On 10th of September, the European Commission President-elected Jean-Claude Juncker unveiled the transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (now called Internal Market, Industry, Entrepreneurship and SMEs).
Dear Member of European Parliament,
The shift of EU pharmaceutical policy will put Europe’s security at risk and is in contradiction with how pharmaceutical policy is (...)
“Placing pharma policy in DG Enterprise was justified. It has traditionally been in DG Enterprise, but was moved to DG Sanco and has once again been instated as an Enterprise competence” said during her hearing Commissioner-designate Elzbieta Bienkowska.
By Dorota Sienkiewicz,Health Equity and Policy Coherence Coordinator, and Martyna Giedrojć, EPHA Policy Officer for Health Systems
The pharmaceutical industry is the biggest sector in the world. In terms of production, (...)
Brussels, 2 October 2014 - We are writing to support Member States who have already expressed their concerns on the decision of European Commission President Elect Jean-Claude Juncker to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of Internal Market and Industry within the new Commission. We would like to ask for your full support to have that decision reversed.
Dear Head of States, Dear Prime (...)